Akouos Reports Third Quarter 2022 Financial Results and Provides Business Highlights
November 14, 2022 07:15 ET
|
Akouos, Inc.
-Received clearance from FDA for the AK-OTOF IND application to initiate a Phase 1/2, first in human, pediatric clinical trial -Continued progress toward planned IND submission for AK-antiVEGF in...
Akouos Receives FDA Clearance of its IND Application for AK-OTOF, a Gene Therapy Intended for the Treatment of OTOF-mediated Hearing Loss
September 13, 2022 07:00 ET
|
Akouos, Inc.
-The IND for AK-OTOF is the first to receive FDA clearance for a genetic form of hearing loss and the first for an AAV vector therapy with the potential to treat an inner ear condition -Akouos plans...
Akouos Reports Second Quarter 2022 Financial Results and Provides Business Highlights
August 15, 2022 07:00 ET
|
Akouos, Inc.
Submitted IND for AK-OTOF to FDA Continued progress toward planned IND submission for AK-antiVEGF Presented new nonclinical data at ASGCT supporting the proposed clinical development of AK-OTOF and...
Akouos Presents Nonclinical Data Supporting the Planned Clinical Development of AK-OTOF and Strategies for Regulated Gene Expression in the Inner Ear at the American Society of Gene and Cell Therapy 25th Annual Meeting
May 19, 2022 07:00 ET
|
Akouos, Inc.
- Nonclinical data demonstrate that a single intracochlear administration of an AAVAnc80 vector led to durable restoration of auditory function and was well tolerated, supporting planned clinical...
Akouos Reports First Quarter 2022 Financial Results and Provides Business Highlights
May 12, 2022 07:45 ET
|
Akouos, Inc.
- Continued progress toward planned IND submissions for AK-OTOF in the first half of 2022 and AK-antiVEGF in 2022 - Presenting new nonclinical data at ASGCT supporting the planned clinical...
Akouos to Present at Bank of America 2022 Healthcare Conference
May 04, 2022 07:00 ET
|
Akouos, Inc.
BOSTON, May 04, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with...
Akouos to Present at the American Society of Gene and Cell Therapy 25th Annual Meeting
May 03, 2022 07:00 ET
|
Akouos, Inc.
BOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling...
Akouos Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights
March 29, 2022 08:00 ET
|
Akouos, Inc.
- Advanced toward planned IND submissions for AK-OTOF in the first half of 2022 and AK-antiVEGF in 2022 - Presented data at ARO demonstrating potential of precision genetic medicine platform to...
Akouos to Participate in Upcoming March Virtual Investor Conferences
March 24, 2022 07:00 ET
|
Akouos, Inc.
BOSTON, March 24, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with...
Akouos Appoints Aaron Tward, M.D., Ph.D., as Chief Scientific Officer
March 10, 2022 07:00 ET
|
Akouos, Inc.
BOSTON, March 10, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling...